المؤلفون: Antti Nätynki, Päivi Leisti, Jussi Tuusa, Outi Varpuluoma, Laura Huilaja, Kentaro Izumi, Sanna-Kaisa Herukka, Olavi Ukkola, Juhani Junttila, Nina Kokkonen, Kaisa Tasanen

المصدر: Frontiers in Immunology, Vol 13 (2022)

مصطلحات موضوعية: bullous pemphigoid, autoimmunity, BP180, gliptins, DPP4, SDF-1 (CXCL12), Immunologic diseases. Allergy, RC581-607

الوصف: The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP autoantigen BP180 in serum samples from patients with type 2 diabetes (T2D) with preceding gliptin medication (n = 136) or without (n = 136). Sitagliptin was the most frequently prescribed gliptin (125/136 patients). Using an ELISA assay, we showed that IgG autoantibodies against the immunodominant NC16A domain of BP180 were found in 5.9% of gliptin treated and in 6.6% of non-gliptin treated T2D patients. We found that 28% of gliptin treated patients had IgG autoantibodies recognizing the native full-length BP180 in ELISA, but among non-gliptin treated the seropositivity was even higher, at 32%. Further ELISA analysis of additional serum samples (n = 57) found no major changes in the seropositivity against BP180 during a follow-up period of about nine years. In immunoblotting, full-length BP180 was recognized by 71% of gliptin treated and 89% of non-gliptin treated T2D patients, but only by 46% of the age-and sex-matched controls. The chemokine stromal derived factor-1(SDF-1/CXCL12) is one of the major substrates of DPP4. Immunostainings showed that the expression of SDF-1 was markedly increased in the skin of BP patients, but not affected by prior gliptin treatment. We found that the use of gliptins decreased the serum level of SDF-1α in both BP and T2D patients. Our results indicate that the autoantibodies against the linear full-length BP180 are common in patients with T2D, but seropositivity is unaffected by the use of sitagliptin.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fimmu.2022.942131/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/d7f5e08f1fb840e0bb3ba84f768e5e58Test

المؤلفون: Nätynki, A. (Antti), Leisti, P. (Päivi), Tuusa, J. (Jussi), Varpuluoma, O. (Outi), Huilaja, L. (Laura), Izumi, K. (Kentaro), Herukka, S.-K. (Sanna-Kaisa), Ukkola, O. (Olavi), Junttila, J. (Juhani), Kokkonen, N. (Nina), Tasanen, K. (Kaisa)

مصطلحات موضوعية: BP180, DPP4, SDF-1 (CXCL12), autoimmunity, bullous pemphigoid, gliptins

الوصف: The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP autoantigen BP180 in serum samples from patients with type 2 diabetes (T2D) with preceding gliptin medication (n = 136) or without (n = 136). Sitagliptin was the most frequently prescribed gliptin (125/136 patients). Using an ELISA assay, we showed that IgG autoantibodies against the immunodominant NC16A domain of BP180 were found in 5.9% of gliptin treated and in 6.6% of non-gliptin treated T2D patients. We found that 28% of gliptin treated patients had IgG autoantibodies recognizing the native full-length BP180 in ELISA, but among non-gliptin treated the seropositivity was even higher, at 32%. Further ELISA analysis of additional serum samples (n = 57) found no major changes in the seropositivity against BP180 during a follow-up period of about nine years. In immunoblotting, full-length BP180 was recognized by 71% of gliptin treated and 89% of non-gliptin treated T2D patients, but only by 46% of the age-and sex-matched controls. The chemokine stromal derived factor-1(SDF-1/CXCL12) is one of the major substrates of DPP4. Immunostainings showed that the expression of SDF-1 was markedly increased in the skin of BP patients, but not affected by prior gliptin treatment. We found that the use of gliptins decreased the serum level of SDF-1α in both BP and T2D patients. Our results indicate that the autoantibodies against the linear full-length BP180 are common in patients with T2D, but seropositivity is unaffected by the use of sitagliptin.

وصف الملف: application/pdf

الإتاحة: http://urn.fi/urn:nbn:fi-fe2023060252179Test

المؤلفون: Franziska Eckert, Karin Schilbach, Lukas Klumpp, Lilia Bardoscia, Efe Cumhur Sezgin, Matthias Schwab, Daniel Zips, Stephan M. Huber

المصدر: Frontiers in Immunology, Vol 9 (2018)

مصطلحات موضوعية: immunotherapy, cancer radiotherapy, CXCR4, SDF-1 (CXCL12), T cells, dendritic cells, Immunologic diseases. Allergy, RC581-607

الوصف: Cancer immunotherapy has been established as standard of care in different tumor entities. After the first reports on synergistic effects with radiotherapy and the induction of abscopal effects—tumor shrinkage outside the irradiated volume attributed to immunological effects of radiotherapy—several treatment combinations have been evaluated. Different immunotherapy strategies (e.g., immune checkpoint inhibition, vaccination, cytokine based therapies) have been combined with local tumor irradiation in preclinical models. Clinical trials are ongoing in different cancer entities with a broad range of immunotherapeutics and radiation schedules. SDF-1 (CXCL12)/CXCR4 signaling has been described to play a major role in tumor biology, especially in hypoxia adaptation, metastasis and migration. Local tumor irradiation is a known inducer of SDF-1 expression and release. CXCR4 also plays a major role in immunological processes. CXCR4 antagonists have been approved for the use of hematopoietic stem cell mobilization from the bone marrow. In addition, several groups reported an influence of the SDF-1/CXCR4 axis on intratumoral immune cell subsets and anti-tumor immune response. The aim of this review is to merge the knowledge on the role of SDF-1/CXCR4 in tumor biology, radiotherapy and immunotherapy of cancer and in combinatorial approaches.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/article/10.3389/fimmu.2018.03018/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/b9be97b9a760414ba991e81dadfab52cTest

المؤلفون: Antti Nätynki, Päivi Leisti, Jussi Tuusa, Outi Varpuluoma, Laura Huilaja, Kentaro Izumi, Sanna-Kaisa Herukka, Olavi Ukkola, Juhani Junttila, Nina Kokkonen, Kaisa Tasanen

مصطلحات موضوعية: Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, bullous pemphigoid, BP180, gliptins, DPP4, SDF-1 (CXCL12)

الوصف: The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP autoantigen BP180 in serum samples from patients with type 2 diabetes (T2D) with preceding gliptin medication (n = 136) or without (n = 136). Sitagliptin was the most frequently prescribed gliptin (125/136 patients). Using an ELISA assay, we showed that IgG autoantibodies against the immunodominant NC16A domain of BP180 were found in 5.9% of gliptin treated and in 6.6% of non-gliptin treated T2D patients. We found that 28% of gliptin treated patients had IgG autoantibodies recognizing the native full-length BP180 in ELISA, but among non-gliptin treated the seropositivity was even higher, at 32%. Further ELISA analysis of additional serum samples (n = 57) found no major changes in the seropositivity against BP180 during a follow-up period of about nine years. In immunoblotting, full-length BP180 was recognized by 71% of gliptin treated and 89% of non-gliptin treated T2D patients, but only by 46% of the age-and sex-matched controls. The chemokine stromal derived factor-1(SDF-1/CXCL12) is one of the major substrates of DPP4. Immunostainings showed that the expression of SDF-1 was markedly increased in the skin of BP patients, but not affected by prior gliptin treatment. We found that the use of gliptins decreased the serum level of SDF-1α in both BP and T2D patients. Our results indicate that the autoantibodies against the linear full-length BP180 are common in patients with T2D, but seropositivity is unaffected by the use of sitagliptin.

العلاقة: https://figshare.com/articles/dataset/DataSheet_1_Use_of_gliptins_reduces_levels_of_SDF-1_CXCL12_in_bullous_pemphigoid_and_type_2_diabetes_but_does_not_increase_autoantibodies_against_BP180_in_diabetic_patients_docx/20365980Test

الإتاحة: https://doi.org/10.3389/fimmu.2022.942131.s001Test
https://figshare.com/articles/dataset/DataSheet_1_Use_of_gliptins_reduces_levels_of_SDF-1_CXCL12_in_bullous_pemphigoid_and_type_2_diabetes_but_does_not_increase_autoantibodies_against_BP180_in_diabetic_patients_docx/20365980Test

المؤلفون: Eckert, Franziska, Schilbach, Karin, Klumpp, Lukas, Bardoscia, Lilia, Sezgin, Efe Cumhur, Schwab, Matthias, Zips, Daniel, Huber, Stephan M.

المصدر: Frontiers in Immunology

مصطلحات موضوعية: CXCR4, Clinical Trials as Topic, Receptors, CXCR4, Immunology, T cells, Review, NK cells, Chemoradiotherapy, SDF-1 (CXCL12), regulatory T cells, Chemokine CXCL12, Hematopoietic Stem Cell Mobilization, Gene Expression Regulation, Neoplastic, Antineoplastic Agents, Immunological, Treatment Outcome, Bone Marrow, Neoplasms, cancer radiotherapy, Humans, dendritic cells, Immunotherapy, Signal Transduction

الوصف: Cancer immunotherapy has been established as standard of care in different tumor entities. After the first reports on synergistic effects with radiotherapy and the induction of abscopal effects-tumor shrinkage outside the irradiated volume attributed to immunological effects of radiotherapy-several treatment combinations have been evaluated. Different immunotherapy strategies (e.g., immune checkpoint inhibition, vaccination, cytokine based therapies) have been combined with local tumor irradiation in preclinical models. Clinical trials are ongoing in different cancer entities with a broad range of immunotherapeutics and radiation schedules. SDF-1 (CXCL12)/CXCR4 signaling has been described to play a major role in tumor biology, especially in hypoxia adaptation, metastasis and migration. Local tumor irradiation is a known inducer of SDF-1 expression and release. CXCR4 also plays a major role in immunological processes. CXCR4 antagonists have been approved for the use of hematopoietic stem cell mobilization from the bone marrow. In addition, several groups reported an influence of the SDF-1/CXCR4 axis on intratumoral immune cell subsets and anti-tumor immune response. The aim of this review is to merge the knowledge on the role of SDF-1/CXCR4 in tumor biology, radiotherapy and immunotherapy of cancer and in combinatorial approaches.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::b95f8f67868fc707ee0fa90a4d30927eTest
http://europepmc.org/articles/PMC6308162Test

المؤلفون: Kowalski, Kamil, Archacki, Rafał, Archacka, Karolina, Stremińska, Władysława, Paciorek, Anna, Gołąbek, Magdalena, Ciemerych, Maria A., Brzoska, Edyta

المصدر: Journal of Cachexia, Sarcopenia and Muscle

مصطلحات موضوعية: Myoblast, Differentiation, Regeneration, Skeletal muscle, Original Article, Original Articles, Sdf‐1 (CXCL12), Stem cells, G‐CSF

الوصف: Background The skeletal muscle has the ability to regenerate after injury. This process is mediated mainly by the muscle specific stem cells, that is, satellite cells. In case of extensive damage or under pathological conditions, such as muscular dystrophy, the process of muscle reconstruction does not occur properly. The aim of our study was to test whether mobilized stem cells, other than satellite cells, could participate in skeletal muscle reconstruction. Methods Experiments were performed on wild‐type mice and mice lacking the functional Pax7 gene, that is, characterized by the very limited satellite cell population. Gastrocnemius mice muscles were injured by cardiotoxin injection, and then the animals were treated by stromal derived factor‐1 (Sdf‐1) with or without granulocyte‐colony stimulating factor (G‐CSF) for 4 days. The muscles were subjected to thorough assessment of the tissue regeneration process using histological and in vitro methods, as well as evaluation of myogenic factors' expression at the transcript and protein levels. Results Stromal derived factor‐1 alone and Sdf‐1 in combination with G‐CSF significantly improved the regeneration of Pax7−/− skeletal muscles. The Sdf‐1 and G‐CSF treatment caused an increase in the number of mononucleated cells associated with muscle fibres. Further analysis showed that Sdf‐1 and G‐CSF treatment led to the rise in the number of CD34+ and Cxcr4+ cells and expression of Cxcr7. Conclusions Stromal derived factor‐1 and G‐CSF stimulated regeneration of the skeletal muscles deficient in satellite cells. We suggest that mobilized CD34+, Cxcr4+, and Cxcr7+ cells can efficiently participate in the skeletal muscle reconstruction and compensate for the lack of satellite cells.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::bd0c25a56a57df497d5343cfec6e05cdTest
http://europepmc.org/articles/PMC4863826Test

مصطلحات موضوعية: Breast cancer, Menstrual hormones, Monocyte Chemotactic Protein-1 (MCP-1/CCL2), Prognosis, Stromal Cell-derived Factor 1-? (SDF-1?/CXCL12)

الوصف: Introduction The chemokines Stromal Cell-Derived Factor-1? (SDF-1?/CXCL12) and Monocyte Chemotactic Protein-1 (MCP-1/CCL2) have been implicated in breast cancer progression. We recently reported elevated systemic MCP-1 in breast cancer patients. This study investigated circulating levels of SDF-1? in breast cancer patients, and addressed potential hormonal regulation of these two potent chemokines. Methods SDF-1? levels were determined by ELISA in 114 breast cancer patients and 85 controls, and correlated with clinical data. Blood samples were collected from 36 healthy premenopausal volunteers weekly for four weeks to measure Luteinising Hormone (LH), Follicular Stimulating Hormone (FSH), Oestradiol and Progesterone using a Bayer ADVIA? Centaur Immunoassay system, in parallel with SDF-1? and MCP-1. CXCL12 expression was determined using RQ-PCR in primary tumour stromal cells (n = 16) harvested at surgery. Results Plasma SDF-1? was significantly higher in breast cancer patients than age-matched controls and had a significant correlation with tumour grade and epithelial subtype. Investigation of menstrual variations of these chemokines revealed lower SDF-1? levels in the mid-luteal phase of the menstrual cycle and a significant positive correlation with circulating Oestradiol. MCP-1 levels showed no correlation with menstrual hormones. There was a trend towards increased CXCL12 expression in tumour compared to normal stromal cells. Conclusions The elevated level of SDF-1? detected in breast cancer patients, and it?s correlation with prognostic indicators, highlights the importance of this chemokine in disease progression. Elucidation of factors influencing chemokine secretion supports clarification of their role in tumourigenesis. ; phone: +353-91-524390 (Dwyer, Roisin M.) ; roisin.dwyer@nuigalway.ie (Dwyer, Roisin M.) ; Department of Surgery, Clinical Science Institute, National University of Ireland, Galway (N.U.I.G) - Galway - IRELAND (Potter, Shirley M.) ; Department of Surgery, Clinical Science ...

العلاقة: 0167-6806 (pISSN); 1573-7217 (eISSN); 10549 (JournalID); s10549-008-0078-2 (publisherID); 78 (ArticleID); http://hdl.handle.net/2262/42133Test; Breast Cancer Research and Treatment; 115; 279; 287

الإتاحة: https://doi.org/10.1007/s10549-008-0078-2Test
http://hdl.handle.net/2262/42133Test